



Job title:	Head of Radiochemistry
Location:	New York, NY

Company:

Actinium Pharmaceuticals is a pioneer in the development of targeted radiotherapies intended to meaningfully improve outcomes for patients with advanced cancers including relapsed or refractory disease who have failed existing therapies. We are advancing a pipeline of differentiated clinical stage product candidates focused on validated cancer targets.

Our current pipeline is focused on indications in myeloid malignancies, solid tumors and conditioning for cell and gene therapies that we believe have high unmet needs that are not addressed by currently available treatment options. We are advancing two clinical stage product candidates that are directed against validated cancer targets. Actinium is advancing its lead product candidate Actimab-A, a CD33 targeting therapeutic, as potential backbone therapy in acute myeloid leukemia and other myeloid malignancies leveraging the mutation agnostic alpha-emitter radioisotope payload Ac-225. We are also evaluating Actimab-A's potential to synergize with PD-1 immune checkpoint inhibitors in solid tumor indications. Iomab-ACT, Actinium's next generation conditioning candidate, is being developed with the goal of improving patient access and outcomes for potentially curative cell and gene therapies. Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with r/r AML, which Actinium is seeking a potential strategic partner for the U.S. ATNM-400 is Actinium's novel non-PSMA targeting Ac-225 radiotherapy for prostate cancer, which is supported by preclinical data and is being advanced to clinical trials. In addition, the company's R&D efforts are primarily focused on advancing several preclinical programs for solid tumor indications.

Our goal is to create a specialty radiopharmaceutical company with capabilities across radioisotope production, final drug product manufacturing, preclinical R&D and clinical development. We are deploying our technologies and capabilities, which we believe to be industry-leading, and intellectual property with approximately 230 issued and pending patents worldwide, to develop targeted and next-generation radiotherapies.

Job Overview:

As a recognized pioneer in the development of targeted radiotherapies, Actinium Pharmaceuticals is rapidly building and advancing a clinical-stage portfolio of promising radiopharmaceutical drug candidates. With this growth, the Company is seeking an experienced, talented and energetic scientist and leader to direct and manage the Discovery and Translational Research programs, support and extend the Company's intellectual property portfolio and advance the development of the Company's proprietary technology for generating and testing novel radiopharmaceutical agents. This role will be responsible for the development and execution of the R&D strategy to drive the value, impact, and opportunity of the Company's science, pipeline assets and platform technology.

The selected candidate will have a strong scientific foundation and a demonstrated track record of producing results in Oncology Drug Discovery and Development for targeted radiotherapies. The candidate will be expected to develop and execute strategic research initiatives, investigate and develop the science



to support novel radioconjugate therapeutic approaches and their clinical advancement. The candidate will also assist in providing background and experimental support for the advancement of the Company's novel intellectual property initiatives.

The Head of Radiochemistry must have significant experience in the biopharmaceutical industry and/or academia, particularly involving the Discovery and Development of targeted radiotherapies and/or diagnostics for Oncology. The candidate must have demonstrated experience in experimental design and execution of radioconjugate therapeutics and/or diagnostics, with demonstrated accomplishments and an impactful publication record. The selected individual must possess excellent interpersonal skills, team management experience and strong written and oral communication abilities.

This role reports to the EVP, Head of R&D or a company designee.

Key Responsibilities:

- Direct and manage the Research & Development programs for targeted radiotherapies
- Lead and direct laboratory preclinical studies including radioconjugation, in vitro/in vivo pharmacology/efficacy, and preclinical dosimetry to guide first-in-human dose predictions
- Lead a multidisciplinary team of Ph.D. scientists and Research Associates
- Help develop and execute the R&D strategy to drive the value, impact, and opportunity of the Company's science, pipeline assets and platform technology
- Support and extend the Company's intellectual property portfolio and advance the development of our proprietary technology for generating and testing novel radiopharmaceutical agents
- Drive the selection and implementation of radionuclides and conjugation strategies aligned with therapeutic goals for Oncology indications
- Cross-functional partnership with CMC, Clinical, and Regulatory team members to drive IND-enabling activities and preclinical translational data for early Development programs
- Establish and manage collaborations with academic labs, CROs, and industry partners

Qualifications:

- Ph.D. in the Life Sciences is essential, preferably in Radiochemistry
- At least 12-15 years of experience in academia and/or biopharmaceutical industry with evidence of advancing radiopharmaceutical drugs from Discovery to Clinical Development for Oncology indications, including IND-filings.
- Must be organized and capable of managing and leading lab operations
- Must have deep knowledge of analytical methods (HPLC, TLC, GC, ICP-MS, gamma spectrometry) to assess radiochemical purity, stability, and specific activity; experience in cancer cell biology is preferred
- Must be scientifically curious and energetic to drive innovation with critical thinking and strong business acumen of the biotech industry
- Must have strong written communication skills, capable of generating written reports, IND filings, scientific presentations and publications
- Must have strong interpersonal and oral communication skills
- Must be a problem solver, creative, and resourceful
- Ability to integrate quickly in a fast-paced, results driven, high performing matrixed organization



Compensation will be commensurate with experience. Actinium offers competitive base salaries, performance bonuses, equity incentive plans, 401(K) with company matching and comprehensive health benefits.